Equities analysts expect ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) to announce earnings of ($0.09) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for ContraVir Pharmaceuticals’ earnings. ContraVir Pharmaceuticals posted earnings of ($0.16) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 43.8%. The business is scheduled to announce its next quarterly earnings report on Wednesday, September 27th.

On average, analysts expect that ContraVir Pharmaceuticals will report full-year earnings of ($0.41) per share for the current fiscal year. For the next fiscal year, analysts forecast that the business will report earnings of ($0.41) per share. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that cover ContraVir Pharmaceuticals.

Separately, Noble Financial restated a “buy” rating on shares of ContraVir Pharmaceuticals in a research report on Friday, April 21st.

A hedge fund recently raised its stake in ContraVir Pharmaceuticals stock. Vanguard Group Inc. increased its stake in shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 17.9% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,414,475 shares of the biopharmaceutical company’s stock after buying an additional 366,192 shares during the period. Vanguard Group Inc. owned 3.79% of ContraVir Pharmaceuticals worth $1,400,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 6.42% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2017/08/16/zacks-analysts-expect-contravir-pharmaceuticals-inc-ctrv-to-announce-0-09-eps.html.

ContraVir Pharmaceuticals (CTRV) traded up 4.717% during mid-day trading on Wednesday, hitting $0.555. 418,785 shares of the company’s stock were exchanged. The stock’s market cap is $35.36 million. ContraVir Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $2.65. The stock’s 50 day moving average price is $0.58 and its 200-day moving average price is $1.02.

About ContraVir Pharmaceuticals

ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100.

Get a free copy of the Zacks research report on ContraVir Pharmaceuticals (CTRV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ContraVir Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.